Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: 46 - The Untold Story

Should you book in your second COVID-19 booster? Here's how Israel's fourth dose changed the fight against Omicron

For Australians over 30, a fourth COVID-19 vaccine jab is now available. In Israel, the first country in the world to embrace the second booster, the benefits for some people were dramatic.

ABC News

New Google study reveals you've probably been pronouncing 25 brands like Nike, Adidas and Hermès wrong

Over the years, many have taken to search engine Google to find out exactly how to pronounce big name brands correctly.

Chronicle Live

Less talk, more action needed to reform IP for all

IP laws are supposed to work to aid pharmaceutical innovation in rich nations. Can a new system support treating illnesses rife in developing economies, too?

360info

From analysis to the latest developments in health,
read the most diverse news in one place.

A new COVID-19 foe, a really transmissible one, is emerging

BALTIMORE — If you’ve recently been infected with COVID-19 or know someone infected, and you probably do, you can probably blame BA.5, one of five subvariants of omicron and possibly the most transmissible yet.

Tribune News Service

EU backs second COVID booster for over-60s, before variant-adapted vaccines are ready

European Union health agencies on Monday recommended a second COVID-19 booster for everyone over 60, as well as medically vulnerable people, amid a new rise in infections and hospitalisations across Europe.

Reuters

Ask the Pediatrician: What should parents know about COVID-19 vaccine for children under 5?

Q: I have heard that there’s an approved COVID-19 vaccine for children under 5. What do I need to know about it?

Tribune News Service

The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Warning Shots: CureVac Sues BioNTech Over COVID Vax Patents

Pharma giants CureVac are suing Pfizer’s vaccine partner BioNTech over the development of the vaccine credited with saving the world from COVID19.

Zenger

Thinking of mixing and matching COVID-19 vaccine booster shots? There doesn't seem to be much point

Most people will have the Moderna or the Pfizer vaccine for their fourth dose. But the Doherty Institute's head of vaccine and immunisation research says there's practically no difference between them.

ABC News

The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Africa CDC signs with Pfizer for COVID pill for African countries

Pfizer will now supply the COVID-19 pill that is highly effective in preventing hospitalisations and deaths.

Al Jazeera

Australia’s booster doses explained: how to decide if you should get a fourth Covid vaccine and how long to wait

How long should I wait after a third dose? Should I wait for an Omicron-specific vaccine? Your questions answered

The Guardian - AU

COVID-19 boosters 'a matter of urgency' says Prime Minister as infections rise to highest level since February

Australia is expected to follow other parts of the world in expanding eligibility for a fourth COVID-19 vaccine dose to the wider population, with the Prime Minister saying the pandemic "isn't over" while encouraging eligible Australians to get their booster shots.

ABC News

Pfizer vaccines that target Omicron variant pass first step to approval in Australia

The TGA’s ‘provisional determination’ for two vaccines comes as BA.4 and BA.5 subvariants drive new wave of Covid cases

The Guardian - AU

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

What Are Whales Doing With Pfizer

A whale with a lot of money to spend has taken a noticeably bearish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 11 strange trades.

Tribune News Service

How Pfizer won the pandemic, reaping outsize profit and influence

The grinding two-plus years of the pandemic have yielded outsize benefits for one company — Pfizer — making it both highly influential and hugely profitable as COVID-19 continues to infect tens of thousands of people and kill hundreds each day.

StockNews.com

As Covid Cases Decline, is it Time to Drop Pfizer?

Leading drug maker Pfizer (PFE) experienced robust growth over the past year primarily based on the growing demand for its Covid vaccine. However, as Covid cases decline, will the company be able to maintain its growth trajectory? Let’s find out.

The Guardian - UK

What’s the UK’s booster policy ahead of a feared autumn Covid wave?

Tweaked vaccines to tackle Omicron are in trials as JCVI finalises advice for vulnerable groups

Get all your
news in one place.

100's of premium titles.
One news app.

WEKU

FDA says COVID boosters for the fall must target newer omicron types

With immunity waning and the super-contagious omicron family of variants getting better at dodging protection, the Food and Drug Administration decided boosters intended for fall needed an update.

Benzinga

Why Pfizer Stock Is Rising Today

Pfizer Inc (NYSE: PFE) shares are trading higher Thursday after the company and BioNTech SE (NASDAQ: BNTX) announced a new COVID-19 vaccine supply agreement with the U.S. government.

Benzinga

This Analyst Says US Government Buying More COVID-19 Vaccines At Higher Prices

Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced a new COVID-19 vaccine supply agreement with the U.S. government. SVB Leerink says that the new contract implies the price per Comirnaty dose is ~$30.50. Comirnaty U.S. pricing per dose has increased from $19.50 (2020 contracts), to $24 (+23%; 2021 contract), and now to ~$30.50 (+27%). The analysts…

Benzinga

Pfizer Seeks Complete Approval For Paxlovid For High Risk COVID-19 Patients

Pfizer Inc (NYSE:PFE) has submitted a new drug application to the FDA for the approval of Paxlovid for patients at high risk for progression to severe illness from COVID-19. Paxlovid is currently authorized for emergency use to treat mild-to-moderate COVID-19 in adults and pediatric patients at high risk for progression to severe COVID-19,…

Benzinga

Will Palantir, Pfizer And Oracle Stocks Continue Higher In This Trend?

Oracle Corporation (NYSE: ORCL), Pfizer Inc (NYSE: PFE) and Palantir Technologies Inc (NYSE: PLTR) were all trading near to fla

The Independent UK

Tweaked COVID boosters in US must target newer omicron types

U.S. regulators are telling COVID-19 vaccine makers to tweak any booster doses intended for fall so they protect against the newest omicron relatives

Chicago Sun-Times

COVID vaccination reboot coming this fall to add tweaks for new coronavirus variants

The FDA will have to decide the exact recipe. But expect a combination shot that adds protection against omicron or some of its newer relatives to the original vaccine.

1 … 45 46 47 48

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Intellectual Property

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.